Tech Company Financing Transactions
CanSense Funding Round
CanSense, based in Swansea, Wales, secured $1.8 million from Mercia Fund Management, Development Bank of Wales and Nonacus.
Transaction Overview
Company Name
Announced On
3/8/2023
Transaction Type
Venture Equity
Amount
$1,805,000
Round
Undisclosed
Investors
Proceeds Purpose
The company intends to use the funds to further develop the product and carry out clinical trials in order to meet regulatory requirements and bring it to market.
Company Information
Company Status
Private & Independent
Industry
Healthcare Services
Mailing Address
Broomfield And Alexander Charter Court Swansea Enterprise Pa
Swansea, Wales, SA7 9FS
UK
Swansea, Wales, SA7 9FS
UK
Phone
Undisclosed
Website
Email Address
Overview
CanSense: delivering a blood test solution for the early diagnosis of bowel cancer. Bowel cancer (also known as colorectal cancer) is the third most common cancer and the fourth most common cause of deaths globally. It accounts for roughly 1.4 million new cases and 700,000 deaths annually. In Europe bowel cancer is the second most common cancer, with 450,000 new cases per year. Incidence is particularly high and is continuing to rise in developed countries. It is well established that early detection is key to saving lives.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Adam Bryant
Founder
Peter Dunstan
Founder
Dean Harris
Founder
Cerys Jenkins
Browse more venture capital transactions:
Prev: 3/8/2023: DexMat venture capital transaction
Next: 3/8/2023: Fount Global venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to report on every notable VC transaction. All VC database entries reported here are sourced from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs